This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Public Health  • Immunization  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Arch Dermatol. 2004;140:767-768.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

During January 24-December 31, 2003, smallpox vaccine was administered to 39,213 civilian health-care and public health workers in 55 jurisdictions to prepare the United States for a possible terrorist attack using smallpox virus. This report updates information on vaccine-associated adverse events among civilians vaccinated since the beginning of the program and among contacts of vaccinees, received by CDC from the Vaccine Adverse Event Reporting System (VAERS) during August 9-December 31.

In this vaccination program, CDC, the Food and Drug Administration, and state health departments are conducting surveillance for vaccine-associated adverse events among civilian vaccinees.^1-2 As part of the vaccination program, civilian vaccinees receive routine follow-up, and reported adverse events after vaccination receive follow-up as needed. The U.S. Department of Defense is conducting surveillance for vaccine-associated adverse events among military vaccinees and providing follow-up care to those persons with reported adverse events.³

Adverse events associated with smallpox vaccination are classified on . . . [Full Text of this Article]

Reported by: